UROSCAN and UROSCANSEQ: a large-scale multicenter effort towards translation of molecular bladder cancer subtypes into clinical practice – from biobank to RNA-sequencing in real time

References

• Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895–1904.
   PubMed Web of Science ®Google Scholar
• Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21(18):1315–1330.
   PubMed Web of Science ®Google Scholar
• Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27(3):295–300.
   PubMed Web of Science ®Google Scholar
• Liedberg F, Hagberg O, Holmäng S, et al. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scand J Urol. 2015;49(4):290–295.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–866.
   PubMed Web of Science ®Google Scholar
• International collaboration of trialists, medical research council advanced bladder cancer working party (now the national cancer research institute bladder cancer clinical studies group), european organisation for research and treatment of cancer Genito-Urinary tract cancer group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171–2177.
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202–205. discussion 205–206.
   PubMed Web of Science ®Google Scholar
• Malmström P-U, Gårdmark T, Sherif A, et al. Incidence, survival and mortality trends of bladder cancer in Sweden 1997-2016. Scand J Urol. 2019;53(4):193–199.
   PubMed Web of Science ®Google Scholar
• Sjödahl G, Lauss M, Lövgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377–3386.
   PubMed Web of Science ®Google Scholar
• Black PC. Seeking the molecular truth in bladder cancer: biology = genome×(transcriptome)2. Eur Urol. 2017;72(3):366–367.
   PubMed Web of Science ®Google Scholar
• Bessa A, Maclennan S, Enting D, et al. Consensus in bladder cancer research priorities Between patients and healthcare professionals using a four-stage modified delphi method. Eur Urol. 2019;76(2):258–259.
   PubMed Web of Science ®Google Scholar
• National Cancer Register [Internet]. Socialstyrelsen. 2022. https://www.socialstyrelsen.se/en/statistics-and-data/registers/national-cancer-register/
   Google Scholar
• Nationellt kvalitetsregister för urinblåsecancer - RCC [Internet]. 2022. https://www.cancercentrum.se/samverkan/cancerdiagnoser/urinblasa-urinvagar/kvalitetsregister/
   Google Scholar
• Sjödahl G, Eriksson P, Liedberg F, et al. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol. 2017;242(1):113–125.
   PubMed Web of Science ®Google Scholar
• Robertson AG, Kim J, Al-Ahmadie H, TCGA Research Network, et al. Comprehensive molecular characterization of Muscle-Invasive bladder cancer. Cell. 2017;171(3):540–556.e25.
   PubMed Web of Science ®Google Scholar
• Marzouka N-A-D, Eriksson P, Rovira C, et al. A validation and extended description of the lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep. 2018;8(1):3737.
   PubMed Web of Science ®Google Scholar
• Marzouka N-A-D, Eriksson P. multiclassPairs: an R package to train multiclass pair-based classifier. Bioinformatics. 2021;37(18):3043–3044.
   PubMed Web of Science ®Google Scholar
• Eriksson P, Marzouka N-A-D, Sjödahl G, et al. A comparison of rule-based and centroid single-sample multiclass predictors for transcriptomic classification. Bioinformatics. 2022;38(4):1022–1029.
   PubMed Web of Science ®Google Scholar
• Marzouka N-A-D, Eriksson P, Bernardo C, et al. The lund molecular taxonomy applied to non-muscle–invasive urothelial carcinoma. J Mol Diagnostics. 2022;24(9):992–1008. https://www.sciencedirect.com/science/article/pii/S1525157822001908.
   PubMed Web of Science ®Google Scholar
• Solid tumours | Genomic Medicine Sweden [Internet]. 2022. https://genomicmedicine.se/en/solid-tumours/.
   Google Scholar
• Sylvester RJ, Rodríguez O, Hernández V, et al. European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. 2021;79(4):480–488.
   PubMed Web of Science ®Google Scholar
• Patschan O, Sjödahl G, Chebil G, et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol. 2015;68(5):824–832. discussion 835–836.
   PubMed Web of Science ®Google Scholar
• Jackson CL, Chen L, Hardy CS, et al. Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer. J Pathol Clin Res. 2022;8(2):143–154.
   PubMedGoogle Scholar
• Taber A, Christensen E, Lamy P, et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat Commun. 2020;11(1):4858.
   PubMed Web of Science ®Google Scholar
• Sjödahl G, Abrahamsson J, Holmsten K, et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. 2021;S0302-2838(21):02138–02132.
   Google Scholar
• Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–1135.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Necchi A, Park SH, BLC2001 Study Group, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338–348.
   PubMed Web of Science ®Google Scholar
• Netto GJ, Amin MB, Berney DM, et al. The 2022 world health organization classification of tumors of the urinary system and male genital Organs-Part B: prostate and urinary tract tumors. Eur Urol. 2022;82(5):469–482.
   PubMed Web of Science ®Google Scholar
• Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432–437.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Hussain M, Gschwend JE, IMvigor010 Study Group, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):525–537.
   PubMed Web of Science ®Google Scholar